Piper Sandler Maintains Overweight on Oscar Health, Lowers Price Target to $18

Benzinga · 06/09 17:21
Piper Sandler analyst Jessica Tassan maintains Oscar Health (NYSE:OSCR) with a Overweight and lowers the price target from $25 to $18.